Recent Publications by Sankyo Company Limited: |
Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
BACKGROUND: Olmesartan medoxomil (CS-866) is a new orally active... | 12th August, 2006
| Clinical Pharmacology and Biostatistics Department, Sankyo Company Ltd,
| Clin Pharmacokinet. 2005;44(12):1329-42.
|
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
The purpose of this study was to examine whether coadministration of... | 1st March, 2006
| Pharmacology and Molecular Biology Research Laboratories, Sankyo Company,
| J Cardiovasc Pharmacol. 2005 Oct;46(4):556-62.
|
Improvement of single nucleotide polymorphism genotyping by allele-specific PCR using primers modified with an ENA residue.
When we placed an ENA residue into primers at the 3' end, or the n-1, n-2,... | 10th September, 2005
| Lead Discovery Research Laboratories, Sankyo Company Ltd., 2-58, Hiromachi
| Anal Biochem. 2005 May 15;340(2):287-94.
DOI Direct Link |
Brain insulin impairs amyloid-beta(1-40) clearance from the brain.
Cerebral amyloid-beta peptide (Abeta) clearance plays a key role in... | 20th May, 2005
| Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo
| J Neurosci. 2004 Oct 27;24(43):9632-7.
DOI Direct Link |
Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method.
Ultracentrifugation methods have been widely used for the determination of... | 13th November, 2004
| Pharmacokinetics and Drug Delivery Research Laboratories, Sankyo Company,
| J Pharm Sci. 2004 Apr;93(4):847-54.
DOI Direct Link |
Enhancement of the inhibitory activity of oatp antisense oligonucleotides by incorporation of 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) without a loss of subtype selectivity.
Antisense oligonucleotides (AONs) that specifically target the genes of... | 17th August, 2004
| Lead Discovery Research Laboratories, Sankyo Company, Ltd., 2-58,
| Biochemistry. 2004 Apr 20;43(15):4501-10.
DOI Direct Link |
CS-088, an angiotensin type 1 receptor antagonist, ameliorated the impaired blood flow in the optic nerve head of rabbits.
The effect of CS-088, an angiotensin type 1 receptor antagonist, on optic... | 27th February, 2004
| Pharmacology and Molecular Biology Research Laboratories, Sankyo Company
| Ophthalmic Res. 2003 Nov-Dec;35(6):351-4.
DOI Direct Link |
TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis.
TRAIL has been proposed as an anti-inflammatory cytokine in animal models... | 24th October, 2003
| Biomedical Research Laboratories, Sankyo Company, Limited, Tokyo, Japan.
| J Immunol. 2003 Jul 15;171(2):1061-9.
|
Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
We examined the pharmacology of... | 9th August, 2003
| Pharmacology and Molecular Biology Research Laboratories, Sankyo Company
| Eur J Pharmacol. 2002 Dec 20;457(2-3):107-14.
|
